Overview

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Subjects With Chronic Low Back Pain

Status:
Completed

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in subjects with chronic low back pain (> 6 months) associated with moderate radiographic degenerative changes of a disc

Phase:

Phase 3

Details

Lead Sponsor:

Mesoblast, Ltd.

Collaborator:

Quintiles, Inc.

Treatments:

Hyaluronic Acid